Your browser is no longer supported. Please, upgrade your browser.
Curis, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own0.10% Shs Outstand66.03M Perf Week32.39%
Market Cap1.21B Forward P/E- EPS next Y-0.43 Insider Trans-5.69% Shs Float63.00M Perf Month11.14%
Income-29.90M PEG- EPS next Q-0.09 Inst Own76.90% Short Float17.70% Perf Quarter25.65%
Sales10.80M P/S112.08 EPS this Y36.60% Inst Trans7.89% Short Ratio3.86 Perf Half Y1021.49%
Book/sh1.98 P/B6.85 EPS next Y-13.20% ROA-37.20% Target Price17.20 Perf Year1687.17%
Cash/sh1.89 P/C7.18 EPS next 5Y- ROE-380.80% 52W Range0.72 - 17.40 Perf YTD65.69%
Dividend- P/FCF- EPS past 5Y23.80% ROI-18.90% 52W High-22.01% Beta3.01
Dividend %- Quick Ratio17.10 Sales past 5Y6.60% Gross Margin95.10% 52W Low1784.72% ATR1.42
Employees28 Current Ratio17.10 Sales Q/Q-9.10% Oper. Margin- RSI (14)59.59 Volatility26.78% 11.46%
OptionableYes Debt/Eq0.01 EPS Q/Q56.10% Profit Margin- Rel Volume1.25 Prev Close13.07
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume2.89M Price13.57
Recom2.00 SMA2025.06% SMA5023.26% SMA200123.20% Volume3,611,628 Change3.83%
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Jan-22-15Reiterated Oppenheimer Outperform $3 → $5
Jan-21-15Reiterated ROTH Capital Buy $10 → $6
May-09-14Reiterated Oppenheimer Outperform $4.50 → $3
Oct-02-13Initiated Robert W. Baird Outperform $7
Sep-30-13Initiated Chardan Capital Markets Buy $6
Nov-14-12Initiated Stifel Nicolaus Hold
Jan-31-12Reiterated Summer Street Research Buy $5 → $7
Jan-31-12Reiterated Brean Murray Buy $5 → $6
Dec-09-11Initiated Oppenheimer Outperform $6
Oct-06-11Initiated Summer Street Research Buy $5
Sep-22-11Initiated MLV Capital Buy $8.50
Mar-21-11Reiterated Brean Murray Buy $4 → $5
Feb-26-10Reiterated Roth Capital Buy $5 → $4.50
May-13-21 06:42PM  
May-12-21 04:01PM  
May-05-21 08:00AM  
May-04-21 03:00PM  
Apr-19-21 08:00AM  
Apr-07-21 04:01PM  
Apr-06-21 08:00AM  
Mar-25-21 10:17AM  
Mar-19-21 01:42AM  
Mar-17-21 09:05AM  
Mar-16-21 09:00PM  
Mar-10-21 04:30PM  
Mar-09-21 08:00AM  
Feb-19-21 08:00AM  
Feb-17-21 01:03AM  
Feb-09-21 08:00AM  
Feb-02-21 08:00AM  
Jan-14-21 08:00AM  
Jan-08-21 04:01PM  
Jan-05-21 08:00AM  
Dec-22-20 04:05PM  
Dec-14-20 08:00AM  
Dec-11-20 08:44AM  
Dec-10-20 09:52PM  
Dec-09-20 03:02PM  
Dec-08-20 04:13PM  
Dec-07-20 01:30PM  
Dec-02-20 08:40AM  
Nov-24-20 09:51AM  
Nov-10-20 04:54PM  
Nov-04-20 01:29PM  
Nov-02-20 04:01PM  
Oct-21-20 08:00AM  
Oct-14-20 05:01PM  
Sep-18-20 07:05AM  
Sep-10-20 04:01PM  
Aug-04-20 04:01PM  
Jul-28-20 08:00AM  
Jul-07-20 08:00AM  
Jun-21-20 10:09PM  
Jun-11-20 09:25AM  
Jun-10-20 08:00AM  
Jun-04-20 07:24PM  
Jun-03-20 09:33AM  
May-12-20 04:01PM  
May-05-20 08:00AM  
Apr-07-20 08:00AM  
Apr-03-20 04:01PM  
Mar-19-20 04:01PM  
Mar-12-20 08:00AM  
Feb-27-20 08:00AM  
Feb-06-20 08:30AM  
Jan-13-20 08:00AM  
Jan-08-20 04:31PM  
Jan-07-20 08:05AM  
Dec-23-19 06:24PM  
Dec-22-19 08:33AM  
Dec-06-19 07:26AM  
Nov-20-19 10:07PM  
Nov-06-19 09:05AM  
Nov-05-19 07:00AM  
Oct-31-19 04:16PM  
Oct-29-19 08:00AM  
Oct-04-19 04:05PM  
Sep-26-19 08:00AM  
Sep-23-19 12:07PM  
Sep-12-19 08:00AM  
Aug-06-19 04:01PM  
Jul-30-19 08:00AM  
Jul-25-19 03:49PM  
Jul-05-19 04:01PM  
Jun-12-19 07:00AM  
May-21-19 11:20AM  
May-14-19 04:29PM  
May-07-19 08:00AM  
May-06-19 08:00AM  
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dentzer James EPresident & CEOJan 26Sale10.593,09432,75867,268Jan 26 06:20 PM
Dentzer James EPresident & CEOJan 25Sale10.962,28325,02270,362Jan 26 06:20 PM